Charles Schwab’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.5M | Sell |
790,812
-17,377
| -2% | -$519K | ﹤0.01% | 1651 |
|
|
2025
Q4 | $30.9M | Sell |
808,189
-40,167
| -5% | -$1.31M | ﹤0.01% | 1475 |
|
|
2025
Q3 | $20.3M | Buy |
848,356
+77,060
| +10% | +$1.45M | ﹤0.01% | 1732 |
|
|
2025
Q2 | $11.4M | Buy |
771,296
+86,753
| +13% | +$1.44M | ﹤0.01% | 1950 |
|
|
2025
Q1 | $12.3M | Buy |
684,543
+22,940
| +3% | +$466K | ﹤0.01% | 1857 |
|
|
2024
Q4 | $11.5M | Buy |
661,603
+94,194
| +17% | +$1.67M | ﹤0.01% | 1952 |
|
|
2024
Q3 | $7.94M | Sell |
567,409
-1,184
| -0.2% | -$12.3K | ﹤0.01% | 2148 |
|
|
2024
Q2 | $4.67M | Buy |
568,593
+13,121
| +2% | +$88.4K | ﹤0.01% | 2388 |
|
|
2024
Q1 | $4.28M | Buy |
555,472
+15,985
| +3% | +$135K | ﹤0.01% | 2337 |
|
|
2023
Q4 | $4.85M | Sell |
539,487
-26,432
| -5% | -$192K | ﹤0.01% | 2324 |
|
|
2023
Q3 | $5.06M | Buy |
565,919
+25,566
| +5% | +$361K | ﹤0.01% | 2260 |
|
|
2023
Q2 | $8.3M | Buy |
540,353
+38,023
| +8% | +$692K | ﹤0.01% | 1995 |
|
|
2023
Q1 | $11.3M | Buy |
502,330
+39,219
| +8% | +$834K | ﹤0.01% | 1812 |
|
|
2022
Q4 | $9.74M | Buy |
463,111
+269
| +0.1% | +$5.7K | ﹤0.01% | 1875 |
|
|
2022
Q3 | $11.4M | Sell |
462,842
-7,305
| -2% | -$189K | ﹤0.01% | 1764 |
|
|
2022
Q2 | $11.4M | Sell |
470,147
-1,733
| -0.4% | -$43.6K | ﹤0.01% | 1770 |
|
|
2022
Q1 | $12.2M | Buy |
471,880
+13,560
| +3% | +$360K | ﹤0.01% | 1837 |
|
|
2021
Q4 | $14.2M | Sell |
458,320
-5,559
| -1% | -$157K | ﹤0.01% | 1803 |
|
|
2021
Q3 | $11.3M | Sell |
463,879
-176,236
| -28% | -$3.24M | ﹤0.01% | 1939 |
|
|
2021
Q2 | $9.34M | Sell |
640,115
-35,535
| -5% | -$701K | ﹤0.01% | 2040 |
|
|
2021
Q1 | $16.9M | Buy |
675,650
+117,340
| +21% | +$3.24M | 0.01% | 1654 |
|
|
2020
Q4 | $15.2M | Buy |
558,310
+34,708
| +7% | +$810K | 0.01% | 1594 |
|
|
2020
Q3 | $9.67M | Buy |
523,602
+120,248
| +30% | +$2.34M | ﹤0.01% | 1723 |
|
|
2020
Q2 | $8.23M | Buy |
403,354
+57,292
| +17% | +$912K | ﹤0.01% | 1762 |
|
|
2020
Q1 | $5.05M | Buy |
346,062
+5,551
| +2% | +$83.5K | ﹤0.01% | 1829 |
|
|
2019
Q4 | $4.84M | Buy |
340,511
+3,076
| +0.9% | +$39.3K | ﹤0.01% | 2031 |
|
|
2019
Q3 | $3.91M | Buy |
337,435
+18,671
| +6% | +$309K | ﹤0.01% | 2104 |
|
|
2019
Q2 | $6.4M | Buy |
318,764
+26,358
| +9% | +$520K | ﹤0.01% | 1852 |
|
|
2019
Q1 | $6.62M | Buy |
292,406
+17,807
| +6% | +$394K | ﹤0.01% | 1839 |
|
|
2018
Q4 | $6.21M | Buy |
274,599
+5,331
| +2% | +$133K | ﹤0.01% | 1770 |
|
|
2018
Q3 | $7.74M | Sell |
269,268
-32,266
| -11% | -$922K | 0.01% | 1797 |
|
|
2018
Q2 | $8.22M | Buy |
301,534
+5,998
| +2% | +$160K | 0.01% | 1724 |
|
|
2018
Q1 | $6.61M | Buy |
295,536
+5,791
| +2% | +$138K | 0.01% | 1786 |
|
|
2017
Q4 | $6.11M | Buy |
289,745
+71
| +0% | +$1.62K | ﹤0.01% | 1813 |
|
|
2017
Q3 | $7.21M | Buy |
289,674
+11,986
| +4% | +$264K | 0.01% | 1677 |
|
|
2017
Q2 | $5.38M | Buy |
277,688
+73,067
| +36% | +$1.33M | 0.01% | 1772 |
|
|
2017
Q1 | $3.78M | Buy |
204,621
+40,330
| +25% | +$789K | ﹤0.01% | 1920 |
|
|
2016
Q4 | $3.11M | Buy |
164,291
+32,183
| +24% | +$658K | ﹤0.01% | 1977 |
|
|
2016
Q3 | $2.96M | Buy |
132,108
+11,187
| +9% | +$213K | ﹤0.01% | 1937 |
|
|
2016
Q2 | $2.15M | Buy |
120,921
+2,040
| +2% | +$33K | ﹤0.01% | 2038 |
|
|
2016
Q1 | $1.62M | Sell |
118,881
-7,979
| -6% | -$121K | ﹤0.01% | 2146 |
|
|
2015
Q4 | $2.45M | Buy |
126,860
+3,233
| +3% | +$64.6K | ﹤0.01% | 1973 |
|
|
2015
Q3 | $2.5M | Buy |
123,627
+21,319
| +21% | +$631K | ﹤0.01% | 1937 |
|
|
2015
Q2 | $3.39M | Buy |
102,308
+47,484
| +87% | +$1.3M | ﹤0.01% | 1801 |
|
|
2015
Q1 | $1.31M | Buy |
54,824
+2,436
| +5% | +$37.1K | ﹤0.01% | 2270 |
|
|
2014
Q4 | $642K | Buy |
52,388
+7,281
| +16% | +$75.3K | ﹤0.01% | 2538 |
|
|
2014
Q3 | $407K | Buy |
45,107
+12,079
| +37% | +$142K | ﹤0.01% | 2663 |
|
|
2014
Q2 | $388K | Buy |
+33,028
| New | +$448K | ﹤0.01% | 2740 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Charles Schwab's TVTX Position: Q1 2026 in Review
Charles Schwab reduced its Travere Therapeutics (TVTX) stake by 2.2% in Q1 2026, selling an estimated $519K and leaving 790,812 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1651.
Charles Schwab first reported a position in TVTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $30.9M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Charles Schwab held 790,812 shares of Travere Therapeutics worth $23.5M as of Q1 2026.
- Charles Schwab sold 17,377 Travere Therapeutics shares in Q1 2026, an estimated $519K.
- Travere Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #1651 holding.
- Charles Schwab first reported a position in Travere Therapeutics in Q2 2014 and has held it in 48 quarters since.
- Charles Schwab's Travere Therapeutics position peaked at $30.9M in Q4 2025.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.